The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. / El-Ouaghlidi, Andrea; Rehring, Erika; Holst, Jens Juul; Schweizer, Anja; Foley, James; Holmes, David; Nauck, Michael A.

I: The Journal of clinical endocrinology and metabolism, Bind 92, Nr. 11, 11.2007, s. 4165-71.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

El-Ouaghlidi, A, Rehring, E, Holst, JJ, Schweizer, A, Foley, J, Holmes, D & Nauck, MA 2007, 'The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion', The Journal of clinical endocrinology and metabolism, bind 92, nr. 11, s. 4165-71. https://doi.org/10.1210/jc.2006-1932

APA

El-Ouaghlidi, A., Rehring, E., Holst, J. J., Schweizer, A., Foley, J., Holmes, D., & Nauck, M. A. (2007). The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. The Journal of clinical endocrinology and metabolism, 92(11), 4165-71. https://doi.org/10.1210/jc.2006-1932

Vancouver

El-Ouaghlidi A, Rehring E, Holst JJ, Schweizer A, Foley J, Holmes D o.a. The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. The Journal of clinical endocrinology and metabolism. 2007 nov.;92(11):4165-71. https://doi.org/10.1210/jc.2006-1932

Author

El-Ouaghlidi, Andrea ; Rehring, Erika ; Holst, Jens Juul ; Schweizer, Anja ; Foley, James ; Holmes, David ; Nauck, Michael A. / The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion. I: The Journal of clinical endocrinology and metabolism. 2007 ; Bind 92, Nr. 11. s. 4165-71.

Bibtex

@article{7e276506320f4d67b1cc4b73c03e566e,
title = "The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion",
abstract = "BACKGROUND/AIMS: Inhibition of dipeptidyl peptidase 4 by vildagliptin enhances the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). The present study asked whether vildagliptin accentuates glibenclamide-induced hypoglycemia or affects endogenous secretion of GLP-1 and GIP after an oral glucose tolerance test.METHODS: There were 16 healthy male subjects studied on four occasions after an overnight fast in a double-blind, four-way crossover study. In random order, vildagliptin (100 mg) or placebo, with and without glibenclamide (5 mg), was administered 30 min before 75 g oral glucose. Blood was sampled to measure glucose, and total (sum of active and inactive) GLP-1 and GIP. Statistical evaluation was done using repeated-measures ANOVA.RESULTS: Glibenclamide provoked hypoglycemia (CONCLUSIONS: Sulfonylurea-induced hypoglycemia after the oral administration of glibenclamide is not accentuated by the coadministration of vildagliptin. This may be explained by a negative feedback regulation of GLP-1 and GIP secretion that limits the degree to which the active incretin levels are enhanced.",
keywords = "Adamantane, Adult, Algorithms, C-Peptide, Dipeptidyl-Peptidase IV Inhibitors, Drug Interactions, Enzyme-Linked Immunosorbent Assay, Gastric Emptying, Gastric Inhibitory Polypeptide, Glucagon, Glucagon-Like Peptide 1, Glucose, Glyburide, Humans, Hydrocortisone, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Nitriles, Pyrrolidines",
author = "Andrea El-Ouaghlidi and Erika Rehring and Holst, {Jens Juul} and Anja Schweizer and James Foley and David Holmes and Nauck, {Michael A}",
year = "2007",
month = nov,
doi = "10.1210/jc.2006-1932",
language = "English",
volume = "92",
pages = "4165--71",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",
number = "11",

}

RIS

TY - JOUR

T1 - The dipeptidyl peptidase 4 inhibitor vildagliptin does not accentuate glibenclamide-induced hypoglycemia but reduces glucose-induced glucagon-like peptide 1 and gastric inhibitory polypeptide secretion

AU - El-Ouaghlidi, Andrea

AU - Rehring, Erika

AU - Holst, Jens Juul

AU - Schweizer, Anja

AU - Foley, James

AU - Holmes, David

AU - Nauck, Michael A

PY - 2007/11

Y1 - 2007/11

N2 - BACKGROUND/AIMS: Inhibition of dipeptidyl peptidase 4 by vildagliptin enhances the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). The present study asked whether vildagliptin accentuates glibenclamide-induced hypoglycemia or affects endogenous secretion of GLP-1 and GIP after an oral glucose tolerance test.METHODS: There were 16 healthy male subjects studied on four occasions after an overnight fast in a double-blind, four-way crossover study. In random order, vildagliptin (100 mg) or placebo, with and without glibenclamide (5 mg), was administered 30 min before 75 g oral glucose. Blood was sampled to measure glucose, and total (sum of active and inactive) GLP-1 and GIP. Statistical evaluation was done using repeated-measures ANOVA.RESULTS: Glibenclamide provoked hypoglycemia (CONCLUSIONS: Sulfonylurea-induced hypoglycemia after the oral administration of glibenclamide is not accentuated by the coadministration of vildagliptin. This may be explained by a negative feedback regulation of GLP-1 and GIP secretion that limits the degree to which the active incretin levels are enhanced.

AB - BACKGROUND/AIMS: Inhibition of dipeptidyl peptidase 4 by vildagliptin enhances the concentrations of the active form of the incretin hormones glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP). The present study asked whether vildagliptin accentuates glibenclamide-induced hypoglycemia or affects endogenous secretion of GLP-1 and GIP after an oral glucose tolerance test.METHODS: There were 16 healthy male subjects studied on four occasions after an overnight fast in a double-blind, four-way crossover study. In random order, vildagliptin (100 mg) or placebo, with and without glibenclamide (5 mg), was administered 30 min before 75 g oral glucose. Blood was sampled to measure glucose, and total (sum of active and inactive) GLP-1 and GIP. Statistical evaluation was done using repeated-measures ANOVA.RESULTS: Glibenclamide provoked hypoglycemia (CONCLUSIONS: Sulfonylurea-induced hypoglycemia after the oral administration of glibenclamide is not accentuated by the coadministration of vildagliptin. This may be explained by a negative feedback regulation of GLP-1 and GIP secretion that limits the degree to which the active incretin levels are enhanced.

KW - Adamantane

KW - Adult

KW - Algorithms

KW - C-Peptide

KW - Dipeptidyl-Peptidase IV Inhibitors

KW - Drug Interactions

KW - Enzyme-Linked Immunosorbent Assay

KW - Gastric Emptying

KW - Gastric Inhibitory Polypeptide

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Glucose

KW - Glyburide

KW - Humans

KW - Hydrocortisone

KW - Hypoglycemia

KW - Hypoglycemic Agents

KW - Insulin

KW - Male

KW - Nitriles

KW - Pyrrolidines

U2 - 10.1210/jc.2006-1932

DO - 10.1210/jc.2006-1932

M3 - Journal article

C2 - 17698900

VL - 92

SP - 4165

EP - 4171

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 11

ER -

ID: 132049840